“Changes in memory and cognitive health can start decades before symptoms appear. That’s why early diagnosis and intervention are crucial to slowing impact.
A new paper co-authored by GAP with our partners at Eli Lilly and Company, “Interchangeability of blood-based biomarkers and PET to identify Alzheimer’s disease Pathology” published in Alzheimer’s & Dementia shows that blood biomarkers (P-tau 217 and Precivity AD) have high agreement with visual reads of amyloid PET scans (overall percent agreement 90.1% and 80.7%, respectively). The blood tests were also as good as quantitative PET results for identifying patients with positive florbetapir-PET visually read scans. These findings show that blood biomarkers are interchangeable with quantitative amyloid PET for identifying who could benefit from available treatments or clinical trials. This could be a gamechanger for 40% of the people in the US with no access to PET imaging due to where they live, or anyone for whom PET is too costly or otherwise unavailable.
This advancement in the field was enabled in part by the comprehensive, well-characterized dataset provided by the Bio-Hermes-001 participants.
When we started Bio-Hermes-001, we had unique support from partners and collaborators who believed that this endeavor would further research, and we are grateful for their support along with the hard work from our GAP-Net sites, and the selfless volunteers. Thank you again to Abbvie, Alzheimer’s Drug Discovery Foundation (ADDF), Biogen, C2N, Cognivue, EMTherapro, Fujirebio, Gates Ventures, IXICO,?Lilly, Linus Health, Merck, Pentara, Quanterix, Retispec, Roche, SomaLogic, and University of Gothenburg.”
GAP President John Dwyer
To read the full paper visit: https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/dad2.70196